Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications-Reference-Cited by-同舟云学术

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications

Published:2017-03 Issue:2 Volume:6 Page:135-139
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Bednasz Cindy J.¹,Venuto Charles S.¹²,Ma Qing¹,Morse Gene D.¹

Affiliation:

1. AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences; University at Buffalo; Buffalo NY USA

2. Center for Human Experimental Therapeutics; University of Rochester; Rochester NY USA

Funder

National Institutes of Health

University of Rochester Center for Human Experimental Therapeutics

National Institute of Allergy and Infectious Diseases

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.313/fullpdf

Reference32 articles.

1. Menon R Badri P Das U Drug-drug interactions with direct-acting antiviral combination therapy of ABT-450/r, ombitasvir, and dasabuvir 54th Interscience Conference on Antimicrobial Agents and Chemotherapy http://www.natap.org/2014/ICAAC/ICAAC_19.htm

2. Intestinal epithelial barrier disruption through altered mucosal microRNA expression in human immunodeficiency virus and simian immunodeficiency virus infections;Gaulke;J Virol,2014

3. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters;Ogasawara;Drug Metab Pharmacokinet,2010

4. U.S. Food and Drug Administration Drug development and drug interactions: table of substrates, inhibitors and inducers http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm.

5. HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition;Kis;Antimicrob Agents Chemother,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Prescribed Psychotropic Medications in an Opioid Substitution Therapy Cohort;Journal of Dual Diagnosis;2019-09-13

2. HIV and Injection Drug Use: New Approaches to HIV Prevention;Global Virology III: Virology in the 21st Century;2019

3. The clinical pharmacology of integrase inhibitors;Expert Review of Clinical Pharmacology;2018-12-21

4. Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate);PLOS ONE;2018-08-16

5. Drug-Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction;Clinical Pharmacology in Drug Development;2017-03